Organogenesis发布经同行评审的临床试验结果:Affinity™对最棘手复杂的静脉性腿部溃疡具临床益处

美股速递
Jul 28

Organogenesis控股公司(Organogenesis Holdings Inc)近日公布了一项重磅科研成果:其产品Affinity™在治疗最具挑战性、最为复杂的静脉性腿部溃疡中显示出显著临床获益。这一结果已发表于经同行评审的专业学术期刊上,标志着针对难愈性伤口治疗领域的又一项突破性进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10